282 related articles for article (PubMed ID: 25783795)
1. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
Hoffmann VS; Baccarani M; Hasford J; Lindoerfer D; Burgstaller S; Sertic D; Costeas P; Mayer J; Indrak K; Everaus H; Koskenvesa P; Guilhot J; Schubert-Fritschle G; Castagnetti F; Di Raimondo F; Lejniece S; Griskevicius L; Thielen N; Sacha T; Hellmann A; Turkina AG; Zaritskey A; Bogdanovic A; Sninska Z; Zupan I; Steegmann JL; Simonsson B; Clark RE; Covelli A; Guidi G; Hehlmann R
Leukemia; 2015 Jun; 29(6):1336-43. PubMed ID: 25783795
[TBL] [Abstract][Full Text] [Related]
2. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS; Baccarani M; Hasford J; Castagnetti F; Di Raimondo F; Casado LF; Turkina A; Zackova D; Ossenkoppele G; Zaritskey A; Höglund M; Simonsson B; Indrak K; Sninska Z; Sacha T; Clark R; Bogdanovic A; Hellmann A; Griskevicius L; Schubert-Fritschle G; Sertic D; Guilhot J; Lejniece S; Zupan I; Burgstaller S; Koskenvesa P; Everaus H; Costeas P; Lindoerfer D; Rosti G; Saussele S; Hochhaus A; Hehlmann R
Leukemia; 2017 Mar; 31(3):593-601. PubMed ID: 27568522
[TBL] [Abstract][Full Text] [Related]
3. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
[TBL] [Abstract][Full Text] [Related]
5. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
Gurrea Salas D; Glauche I; Tauer JT; Thiede C; Suttorp M
Ann Hematol; 2015 Aug; 94(8):1363-71. PubMed ID: 25894600
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Höglund M; Sandin F; Hellström K; Björeman M; Björkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevärn B; Myhr-Eriksson K; Ohm L; Olsson-Strömberg U; Själander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Blood; 2013 Aug; 122(7):1284-92. PubMed ID: 23843494
[TBL] [Abstract][Full Text] [Related]
7. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
Penot A; Preux PM; Le Guyader S; Collignon A; Herry A; Dufour V; Monnereau A; Woronoff AS; Troussard X; Pons E; Bordessoule D; Maynadié M
Leuk Lymphoma; 2015 Jun; 56(6):1771-7. PubMed ID: 25535815
[TBL] [Abstract][Full Text] [Related]
8. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents.
Millot F; Guilhot J; Suttorp M; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A
Haematologica; 2017 Oct; 102(10):1704-1708. PubMed ID: 28838993
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
Pfirrmann M; Baccarani M; Saussele S; Guilhot J; Cervantes F; Ossenkoppele G; Hoffmann VS; Castagnetti F; Hasford J; Hehlmann R; Simonsson B
Leukemia; 2016 Jan; 30(1):48-56. PubMed ID: 26416462
[TBL] [Abstract][Full Text] [Related]
11. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
12. [Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study].
Kulikov SM; Vinogradova OIu; Chelysheva EIu; Tishchenko IA; Galaĭko MA; Lazareva OV; Senderova OM; Pepeliaeva VM; Meresiĭ SV; Luchinin AS; Ovsepian VA; Miliutina GI; Gavrilova LV; Avdeeva LB; Neverova AL; Turkina AG
Ter Arkh; 2014; 86(7):24-30. PubMed ID: 25314774
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
[TBL] [Abstract][Full Text] [Related]
14. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
15. [Descriptive epidemiology of myeloid leukemia].
Matsuo K; Ito H
Nihon Rinsho; 2009 Oct; 67(10):1847-51. PubMed ID: 19860178
[TBL] [Abstract][Full Text] [Related]
16. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
Pfirrmann M; Clark RE; Prejzner W; Lauseker M; Baccarani M; Saussele S; Guilhot F; Heibl S; Hehlmann R; Faber E; Turkina A; Ossenkoppele G; Höglund M; Zaritskey A; Griskevicius L; Olsson-Strömberg U; Everaus H; Koskenvesa P; Labar B; Sacha T; Zackova D; Cervantes F; Colita A; Zupan I; Bogdanovic A; Castagnetti F; Guilhot J; Hasford J; Hochhaus A; Hoffmann VS
Leukemia; 2020 Aug; 34(8):2138-2149. PubMed ID: 32601376
[TBL] [Abstract][Full Text] [Related]
17. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.
Iriyama N; Hatta Y; Kobayashi S; Uchino Y; Miura K; Kurita D; Kodaira H; Inoue M; Takei M
Int J Hematol; 2014 Oct; 100(4):379-85. PubMed ID: 25092482
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia--from the National to the European Registry--limited experience of a single center.
Vlădăreanu AM; Voican I; Bumbea H; Vasile D; Radesi S; Coriu D; Coliţa A; Tălmaci R; Ilea A
Rom J Intern Med; 2010; 48(1):73-9. PubMed ID: 21180244
[TBL] [Abstract][Full Text] [Related]
19. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia.
Bonifazi F; De Vivo A; Rosti G; Tiribelli M; Russo D; Trabacchi E; Fiacchini M; Montefusco E; Baccarani M
Br J Haematol; 2000 Nov; 111(2):587-95. PubMed ID: 11122107
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib.
Chhikara S; Sazawal S; Singh K; Chaubey R; Pati H; Tyagi S; Mahapatra M; Saxena R
South Asian J Cancer; 2018; 7(4):258-262. PubMed ID: 30430096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]